

PRESS RELEASE

**Neopharmed Gentili acquires the European ORLADEYO® Business from BioCryst Pharmaceuticals establishing a scalable European rare disease presence**

**Milan, 27<sup>th</sup> June 2025** - Neopharmed Gentili ("Neopharmed"), an Italian pharmaceutical company active in the marketing of high-value therapeutic solutions, controlled by the Del Bono Family and two leading international private equity firms, Ardian and Renaissance Partners, announces the acquisition of the European ORLADEYO® (berotralstat) business from BioCryst Pharmaceuticals. ORLADEYO is the first oral, once-daily plasma kallikrein inhibitor indicated for the treatment of Hereditary Angioedema (HAE).

This transaction is consistent with Neopharmed's strategy of replicating its success in Italy at the European level, while strengthening its portfolio by entering the high value and fast-growing rare disease space. Neopharmed is acquiring BioCryst's European organization, which will enable commercial continuity for ORLADEYO available to patients in Europe through the resources, capabilities and know-how BioCryst built in the HAE field. This transaction puts Neopharmed in a strong position to create value beyond ORLADEYO and drive sustainable growth well into the next decade through pipeline expansion in specialty pharmaceuticals and rare disease therapies.

Neopharmed is acquiring a rare disease business that is set to grow 30%+ YoY in 2025, generating c. €50 Million in sales with significant long-term growth runway, and an established and scalable specialty platform to support additional portfolio expansion.

ORLADEYO® and the European team responsible for its success represent a first step in Neopharmed becoming the partner of choice and consolidator of rare disease assets in Europe.

*"This transaction marks the beginning of a new path for Neopharmed Gentili, projecting the company into the international stage and rare disease field, leveraging its deep Italian roots and welcoming a successful and experienced European team."* said **Alessandro Del Bono, President and CEO of Neopharmed Gentili**. *"This acquisition confirms and further strengthens our long-term growth trajectory, consolidating our positioning as a leading European specialty pharmaceutical company. I would like to thank BioCryst's CEO Jon Stonehouse and his team for the collaborative spirit that underpinned our discussions. I would also like to congratulate the Neopharmed team for this transaction which marks a key step in our long-term strategic journey and to thank them for their hard work and commitment to this process."*

*“This transaction is consistent with our strategy of making ORLADEYO available to patients in Europe through the team we built, and puts us in an even stronger position to create value beyond ORLADEYO and sustainable growth well into the next decade through our pipeline and potential external opportunities,” said **Jon Stonehouse, President and CEO of BioCryst.** “We believe Neopharmed Gentili will be able to leverage ORLADEYO and this outstanding team to launch a capital efficient strategy that makes a ton of sense and could develop into a thriving European Rare disease business that could become the partner of choice for U.S. rare disease companies, including BioCryst when we advance additional products to the market.”*

### **Transaction Details**

- Upon closing, which is expected in October 2025 and subject to customary conditions, Neopharmed will pay BioCryst \$250 million upfront for the European assets and rights related to ORLADEYO, and up to \$14 million in future milestones associated with sales in Central and Eastern Europe.
- Neopharmed will be responsible for royalties related to European sales within the framework of BioCryst’s global royalty agreements.
- The transaction will be funded by a combination of available cash and contributions from Neopharmed shareholders.

Centerview Partners UK LLP is serving as exclusive financial advisor, White & Case, LLP is serving as legal advisor, PwC is serving as financial and tax advisor, ZS Associates is serving as commercial advisor and ValueVector is serving as market access & pricing advisor to Neopharmed Gentili.

BofA Securities, Inc. and TD Securities are serving as financial advisors and Skadden, Arps, Slate, Meagher & Flom LLP is serving as legal advisor to BioCryst.

###

### **About Neopharmed Gentili**

Neopharmed Gentili is a pharmaceutical company founded in Italy with historic roots in its territory, which is rapidly expanding beyond national borders thanks to a consolidated and reliable experience in M&A and Licensing transactions, especially with multinational partners. Research, responsibility, and care are the pillars that guide Neopharmed Gentili’s mission to improve the health and quality of life of patients, caregivers, and healthcare personnel. Neopharmed Gentili’s ambition is to help people live long and healthy lives, acting with ethical value and scientific precision, and offering solutions with high therapeutic value. For more information, please visit [www.neogen.it](http://www.neogen.it)

### **About BioCryst Pharmaceuticals**

BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its

expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit [www.biocryst.com](http://www.biocryst.com)

###

**For further informations:**

**Neopharmed Gentili S.p.A.**

*Ottavia Landi*

Mob. 342.3409572 | [o.landi@landi-consulting.com](mailto:o.landi@landi-consulting.com)

**Press office - Value Relations**

*Angela Del Giudice*

Mob. 392.6858392 | [a.delgiudice@vrelations.it](mailto:a.delgiudice@vrelations.it)

*Chiara Farroni*

Mob. 331.4997375 | [c.farroni@vrelations.it](mailto:c.farroni@vrelations.it)